Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Assunto principal
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Breast Cancer Res Treat ; 203(3): 587-598, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37926760

RESUMO

PURPOSE: The Oncotype DX (ODX) test is a commercially available molecular test for breast cancer assay that provides prognostic and predictive breast cancer recurrence information for hormone positive, HER2-negative patients. The aim of this study is to propose a novel methodology to assist physicians in their decision-making. METHODS: A retrospective study between 2012 and 2020 with 333 cases that underwent an ODX assay from three hospitals in the Bourgogne Franche-Comté region (France) was conducted. Clinical and pathological reports were used to collect the data. A methodology based on distributional random forest was developed to predict the ODX score classes (ODX [Formula: see text] and ODX [Formula: see text]) using 9 clinico-pathological characteristics. This methodology can be used particularly to identify the patients of the training cohort that share similarities with the new patient and to predict an estimate of the distribution of the ODX score. RESULTS: The mean age of participants is 56.9 years old. We have correctly classified [Formula: see text] of patients in low risk and [Formula: see text] of patients in high risk. The overall accuracy is [Formula: see text]. The proportion of low risk correct predicted value (PPV) is [Formula: see text]. The percentage of high risk correct predicted value (NPV) is approximately [Formula: see text]. The F1-score and the Area Under Curve (AUC) are of 0.87 and 0.759, respectively. CONCLUSION: The proposed methodology makes it possible to predict the distribution of the ODX score for a patient. This prediction is reinforced by the determination of a family of known patients with follow-up of identical scores. The use of this methodology with the pathologist's expertise on the different histological and immunohistochemical characteristics has a clinical impact to help oncologist in decision-making regarding breast cancer therapy.


Assuntos
Neoplasias da Mama , Humanos , Pessoa de Meia-Idade , Feminino , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/genética , Neoplasias da Mama/terapia , Estudos Retrospectivos , Recidiva Local de Neoplasia/genética , Recidiva Local de Neoplasia/patologia , Prognóstico , Mama/patologia , Perfilação da Expressão Gênica/métodos
2.
Biometrika ; 103(2): 303-317, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27279659

RESUMO

Max-stable processes play an important role as models for spatial extreme events. Their complex structure as the pointwise maximum over an infinite number of random functions makes their simulation difficult. Algorithms based on finite approximations are often inexact and computationally inefficient. We present a new algorithm for exact simulation of a max-stable process at a finite number of locations. It relies on the idea of simulating only the extremal functions, that is, those functions in the construction of a max-stable process that effectively contribute to the pointwise maximum. We further generalize the algorithm by Dieker & Mikosch (2015) for Brown-Resnick processes and use it for exact simulation via the spectral measure. We study the complexity of both algorithms, prove that our new approach via extremal functions is always more efficient, and provide closed-form expressions for their implementation that cover most popular models for max-stable processes and multivariate extreme value distributions. For simulation on dense grids, an adaptive design of the extremal function algorithm is proposed.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA